Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine
- PMID: 1449536
- DOI: 10.1016/0006-2952(92)90077-v
Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine
Abstract
Cellular metabolism studies had demonstrated previously that low cellular concentrations of 2',2'-difluorodeoxycytidine (dFdC) nucleotides are eliminated by deoxycytidylate deaminase (dCMPD), whereas dCMPD activity is inhibited at high cellular dFdC nucleotide levels (Heinemann et al., Cancer Res 52: 533-539, 1992). An assay for measuring dCMPD activity in intact human leukemia cells has now been developed to permit investigations of the interactions of dFdC nucleotides with dCMPD in intact cells in which the regulated nature of this enzyme was not disrupted. Using [14C]dCyd as the substrate, radioactivity that accumulated in dTTP was quantitated after high-pressure liquid chromotography by a radioactive flow detector. The assay was first characterized using either the dCMPD inhibitor tetrahydrodeoxyuridine (H4dUrd) which directly inhibits dCMPD, or thymidine and 5-fluoro-2'-deoxyuridine (FdUrd) which indirectly inhibit and activate dCMPD, respectively, by affecting the cellular dCTP:dTTP value. Measured by this in situ assay, there was a strong correlation between dCMPD activity and dCTP:dTTP levels. Consistent with previous studies using partially purified enzyme, incubation of cells with dFdC resulted in a concentration-dependent inhibition of dCMPD in situ. The mechanism of modulation of dCMPD by dFdC, however, was clearly different from that of thymidine and FdUrd. In addition to the effect of dFdC on cellular dCTP:dTTP, our findings also suggested an additional inhibitory mechanism, possibly a direct interaction between dCMPD and dFdC 5'-triphosphate. Thus, results obtained using this direct assay of dCMPD in intact cells support the hypothesis that dCMPD is inhibited by nucleotides of dFdC.
Similar articles
-
Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine.Biochem Pharmacol. 1989 Nov 15;38(22):4115-21. doi: 10.1016/0006-2952(89)90693-x. Biochem Pharmacol. 1989. PMID: 2688654
-
Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.Cancer Res. 1992 Feb 1;52(3):533-9. Cancer Res. 1992. PMID: 1732039
-
Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.Biochem Pharmacol. 1993 May 5;45(9):1857-61. doi: 10.1016/0006-2952(93)90444-2. Biochem Pharmacol. 1993. PMID: 8494545
-
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10. Semin Oncol. 1995. PMID: 7481842 Review.
-
Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites?Fundam Clin Pharmacol. 2011 Apr;25(2):172-85. doi: 10.1111/j.1472-8206.2010.00823.x. Fundam Clin Pharmacol. 2011. PMID: 20199587 Review.
Cited by
-
Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action.Clin Pharmacokinet. 2020 Dec;59(12):1521-1550. doi: 10.1007/s40262-020-00934-7. Clin Pharmacokinet. 2020. PMID: 33064276 Free PMC article. Review.
-
Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.Mol Oncol. 2016 Jan;10(1):85-100. doi: 10.1016/j.molonc.2015.07.006. Epub 2015 Aug 22. Mol Oncol. 2016. PMID: 26372358 Free PMC article.
-
Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy.PLoS One. 2012;7(12):e50176. doi: 10.1371/journal.pone.0050176. Epub 2012 Dec 11. PLoS One. 2012. PMID: 23239976 Free PMC article.
-
Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin.Br J Cancer. 2005 May 9;92(9):1684-9. doi: 10.1038/sj.bjc.6602564. Br J Cancer. 2005. PMID: 15841076 Free PMC article.
-
Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.Br J Clin Pharmacol. 2018 Jun;84(6):1279-1289. doi: 10.1111/bcp.13557. Epub 2018 Apr 16. Br J Clin Pharmacol. 2018. PMID: 29451684 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical